Security
Allogene Therapeutics, Inc. Common Stock · ALLO
ALLONASDAQCommon stockCurrentCIK 1737287Updated Nov 17, 2026
ALLO price & chart
Loading TradingView…
NASDAQ:ALLO on TradingView ↗About the company
Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T) products for cancer and autoimmune disease. Led by cell therapy veterans applying proven CAR T experience, Allogene is developing a pipeline of off-the-shelf CAR T cell product candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients.
In the news
Allogene Therapeutics Announces Participation in September Investor Conference ↗
Seeking Alpha
Allogene Therapeutics, Inc. (ALLO) Presents at UBS Global Biopharma Conference 2026 Transcript ↗
Allogene Therapeutics, Inc. (ALLO) Reviews Preliminary ALLO-329 Safety and Efficacy Data in Autoimmune Diseases Transcript ↗
Allogene targets ALPHA3 enrollment completion by year-end 2027 while planning midyear 2027 clinical update ↗
Recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 439,771,000Source | 589,120,000Source | 550,091,000Source | 470,593,000Source | 646,883,000Source | 395,958,000Source | 507,982,000Source | 586,350,000Source | 415,905,000Source | 548,710,000Source | 750,128,000Source | 821,579,000Source |
| Property, Plant and Equipment, NetUSD | 75,896,000Source | 88,989,000Source | 67,382,000Source | 78,858,000Source | 92,080,000Source | 70,023,000Source | 82,992,000Source | 95,931,000Source | 72,839,000Source | 86,056,000Source | 109,849,000Source | 112,839,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 37,815,000Source | 51,239,000Source | 38,626,000Source | 52,332,000Source | 170,667,000Source | 30,309,000Source | 42,455,000Source | 51,039,000Source | 51,688,000Source | 75,218,000Source | 109,931,000Source | 61,904,000Source |
| Assets, CurrentUSD | 260,719,000Source | 304,415,000Source | 340,000,000Source | 282,655,000Source | 457,124,000Source | 273,293,000Source | 291,576,000Source | 395,364,000Source | 257,749,000Source | 303,386,000Source | 481,465,000Source | 528,824,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 8,525,000Source | 12,851,000Source | 7,396,000Source | 9,535,000Source | 12,496,000Source | 6,407,000Source | 11,533,000Source | 10,504,000Source | 7,539,000Source | 10,910,000Source | 10,241,000Source | 11,504,000Source |
| Operating Lease, Right-of-Use AssetUSD | 40,935,000Source | 46,313,000Source | 37,739,000Source | 41,966,000Source | 58,385,000Source | 38,819,000Source | 44,075,000Source | 64,483,000Source | 39,888,000Source | 45,205,000Source | 81,964,000Source | 83,592,000Source |
| Other Assets, NoncurrentUSD | 3,513,000Source | 4,970,000Source | 3,692,000Source | 3,828,000Source | 6,439,000Source | 3,531,000Source | 1,900,000Source | 5,159,000Source | 3,615,000Source | 2,325,000Source | 9,389,000Source | 9,564,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 124,442,000Source | 125,372,000Source | 113,916,000Source | 126,032,000Source | 131,845,000Source | 117,083,000Source | 122,589,000Source | 124,983,000Source | 123,363,000Source | 126,531,000Source | 158,118,000Source | 154,697,000Source |
| Stockholders’ equity: | ||||||||||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 223,000Source | 210,000Source | 345,000Source | 220,000Source | 209,000Source | 245,000Source | 219,000Source | 170,000Source | 229,000Source | 212,000Source | 146,000Source | 144,000Source |
| Retained Earnings (Accumulated Deficit)USD | -1,971,899,000Source | -1,759,884,000Source | -2,095,993,000Source | -1,930,499,000Source | -1,693,591,000Source | -2,053,316,000Source | -1,879,556,000Source | -1,627,233,000Source | -2,010,709,000Source | -1,819,823,000Source | -1,334,936,000Source | -1,234,968,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 235,000Source | 157,000Source | -518,000Source | -45,000Source | -780,000Source | -183,000Source | 43,000Source | -927,000Source | 269,000Source | -89,000Source | -5,934,000Source | -9,926,000Source |
| Stockholders' Equity Attributable to ParentUSD | 315,329,000Source | 463,748,000Source | 436,175,000Source | 344,561,000Source | 515,038,000Source | 278,875,000Source | 385,393,000Source | 461,367,000Source | 292,542,000Source | 422,179,000Source | 592,010,000Source | 666,882,000Source |
| Additional Paid in Capital, Common StockUSD | 2,286,770,000Source | 2,223,265,000Source | 2,532,341,000Source | 2,274,885,000Source | 2,209,200,000Source | 2,332,129,000Source | 2,264,687,000Source | 2,089,357,000Source | 2,302,753,000Source | 2,241,879,000Source | 1,932,734,000Source | 1,911,632,000Source |
| Liabilities and EquityUSD | 439,771,000Source | 589,120,000Source | 550,091,000Source | 470,593,000Source | 646,883,000Source | 395,958,000Source | 507,982,000Source | 586,350,000Source | 415,905,000Source | 548,710,000Source | 750,128,000Source | 821,579,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 31,833,000Source | 32,571,000Source | 31,727,000Source | 31,675,000Source | 37,305,000Source | 28,330,000Source | 30,022,000Source | 30,894,000Source | 32,514,000Source | 35,523,000Source | 59,398,000Source | 53,728,000Source |
| Operating Lease, Liability, CurrentUSD | 8,008,000Source | 7,389,000Source | 8,656,000Source | 7,756,000Source | 7,221,000Source | 8,418,000Source | 7,631,000Source | 6,930,000Source | 8,208,000Source | 7,509,000Source | — | 6,002,000Source |
| Accounts Payable, CurrentUSD | 3,699,000Source | 5,506,000Source | 5,964,000Source | 4,851,000Source | 12,936,000Source | 4,933,000Source | 5,058,000Source | 5,779,000Source | 4,270,000Source | 5,394,000Source | 14,688,000Source | 13,890,000Source |
| Operating Lease, Liability, NoncurrentUSD | 77,134,000Source | 85,135,000Source | 70,353,000Source | 79,241,000Source | 86,989,000Source | 72,633,000Source | 81,292,000Source | 88,916,000Source | 75,045,000Source | 83,247,000Source | 93,514,000Source | 95,122,000Source |
| Other Liabilities, NoncurrentUSD | 15,475,000Source | 7,666,000Source | 11,836,000Source | 15,116,000Source | 7,551,000Source | 16,120,000Source | 11,275,000Source | 5,173,000Source | 15,804,000Source | 7,761,000Source | 5,205,000Source | 5,847,000Source |
| Additional Financial Items | ||||||||||||
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 277,100,000Source | 403,400,000Source | 423,600,000Source | 302,600,000Source | 444,600,000Source | 266,900,000Source | 335,500,000Source | 397,300,000Source | 258,300,000Source | 373,100,000Source | — | 576,500,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | -42,607,000Source | -59,733,000Source | -190,886,000Source | -257,590,000Source | -327,265,000Source | -340,414,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | — | 2,869,000Source | 3,099,000Source | 12,359,000Source | 13,639,000Source | 14,200,000Source | 14,300,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 8,270,000Source | 12,175,000Source | 37,642,000Source | 51,743,000Source | 65,951,000Source | 83,600,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | 663,000Source | -336,000Source | -1,231,000Source | -503,000Source | -7,502,000Source | 4,868,000Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | 443,000Source | — | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -12,913,000Source | -52,929,000Source | -149,246,000Source | -200,300,000Source | -237,733,000Source | -220,519,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -29,588,000Source | 6,176,000Source | 95,559,000Source | 75,688,000Source | 163,289,000Source | 106,159,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 9,000Source | 99,000Source | 386,000Source | 694,000Source | 1,516,000Source | 5,191,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 21,122,000Source | 13,990,000Source | 30,157,000Source | 116,675,000Source | 95,695,000Source | 2,950,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -21,379,000Source | -32,763,000Source | -23,530,000Source | -7,937,000Source | 21,251,000Source | -111,410,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 48,107,000Source | 61,531,000Source | 48,918,000Source | 62,624,000Source | 40,601,000Source | 52,747,000Source | 61,980,000Source | 85,510,000Source | 93,447,000Source | 72,196,000Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 8,652,000Source | 13,387,000Source | 12,440,000Source | 8,685,000Source | 8,270,000Source | 12,175,000Source | 37,641,000Source | 51,743,000Source | 66,000,000Source | 83,600,000Source |
| Amortization of Intangible AssetsUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | 277,100,000Source | 403,400,000Source | 423,600,000Source | 302,600,000Source | 266,900,000Source | 335,500,000Source | 258,300,000Source | 373,100,000Source | 448,700,000Source | 576,500,000Source |
| DepreciationUSD | — | — | — | — | — | — | — | — | — | — | 14,199,000Source | 14,295,000Source |
| Equity Method Investment, Other than Temporary ImpairmentUSD | — | — | — | — | — | — | — | — | 0Source | 1,957,000Source | 7,000,000Source | — |
| General and Administrative ExpenseUSD | — | — | 13,737,000Source | 16,333,000Source | 20,839,000Source | 14,281,000Source | 14,089,000Source | 14,991,000Source | 56,781,000Source | 65,205,000Source | 71,673,000Source | 79,305,000Source |
| Income (Loss) from Equity Method InvestmentsUSD | — | — | — | — | — | — | — | 0Source | 0Source | -1,688,000Source | — | — |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | 443,000Source | 0Source | 0Source |
| InterestExpenseNonoperatingUSD | — | — | 344,000Source | 100,000Source | 343,000Source | 268,000Source | 300,000Source | 150,000Source | 1,075,000Source | 181,000Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -41,400,000Source | -66,293,000Source | -42,677,000Source | -50,943,000Source | -42,607,000Source | -59,733,000Source | -190,886,000Source | -257,590,000Source | -327,265,000Source | -340,414,000Source |
| Nonoperating Income (Expense)USD | — | — | 3,501,000Source | 5,481,000Source | 4,243,000Source | 5,876,000Source | 3,485,000Source | 5,458,000Source | 18,429,000Source | 16,052,000Source | 472,000Source | -4,878,000Source |
| Operating ExpensesUSD | — | — | 44,901,000Source | 71,774,000Source | 51,560,000Source | 56,819,000Source | 46,092,000Source | 65,191,000Source | 209,315,000Source | 273,221,000Source | 327,832,000Source | 335,692,000Source |
| Operating Lease, ExpenseUSD | — | — | — | — | — | — | 1,069,000Source | 1,130,000Source | 4,355,000Source | 5,264,000Source | 642,000Source | 2,433,000Source |
| Operating Lease, Lease IncomeUSD | — | — | 700,000Source | — | 700,000Source | 800,000Source | 800,000Source | 300,000Source | 2,600,000Source | — | — | — |
| Other Nonoperating Income (Expense)USD | — | — | -81,000Source | -1,124,000Source | -61,000Source | -43,000Source | 212,000Source | 92,000Source | 215,000Source | -3,920,000Source | -17,835,000Source | -9,444,000Source |
| Payments to Acquire InvestmentsUSD | — | — | — | — | — | — | 101,694,000Source | 50,225,000Source | 138,257,000Source | 361,475,000Source | 438,629,000Source | 248,109,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | 10,002,000Source | — | — | 91,112,000Source | 0Source |
| Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-saleUSD | — | — | — | — | — | — | 72,115,000Source | 56,500,000Source | 234,202,000Source | 432,459,000Source | 597,811,000Source | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 0Source | 0Source | 4,640,000Source | 0Source | — | 0Source | 0Source | 22,000Source | 95,000Source | 156,000Source |
| Operating Income (Loss)USD | — | — | -44,901,000Source | -71,774,000Source | -46,920,000Source | -56,819,000Source | -46,092,000Source | -65,191,000Source | -209,315,000Source | -273,199,000Source | -327,737,000Source | -335,536,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -81,000Source | -1,124,000Source | -61,000Source | -43,000Source | 212,000Source | 92,000Source | 215,000Source | -3,920,000Source | -17,835,000Source | -9,444,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | -190,886,000Source | -257,147,000Source | — | — |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | 443,000Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -41,400,000Source | -66,293,000Source | -42,677,000Source | -50,943,000Source | -42,607,000Source | -59,733,000Source | -190,886,000Source | -257,590,000Source | -327,265,000Source | -340,414,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.19Source | -0.32Source | -0.13Source | -0.23Source | -0.18Source | -0.28Source | -0.87Source | -1.32Source | -2.09Source | -2.38Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.19Source | -0.32Source | -0.13Source | -0.23Source | -0.18Source | -0.28Source | -0.87Source | -1.32Source | -2.09Source | -2.38Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 222,038,680Source | 209,188,551Source | 328,930,269Source | 218,929,548Source | 240,290,782Source | 215,358,619Source | 220,622,669Source | 194,811,756Source | 156,931,778Source | 143,147,165Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 222,038,680Source | 209,188,551Source | 328,930,269Source | 218,929,548Source | 240,290,782Source | 215,358,619Source | 220,622,669Source | 194,811,756Source | 156,931,778Source | 143,147,165Source |
| Interest Expense (non-operating)USD | — | — | 344,000Source | 100,000Source | 343,000Source | 268,000Source | 300,000Source | 150,000Source | 1,075,000Source | 181,000Source | — | — |
| Additional Financial Items | ||||||||||||
| Amortization of Intangible AssetsUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Common Stock, Dividends, Per Share, DeclaredUSD per share | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source |
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | 0Source | — | — |
| General and Administrative ExpenseUSD | — | — | 13,737,000Source | 16,333,000Source | 20,839,000Source | 14,281,000Source | 14,089,000Source | 14,991,000Source | 56,781,000Source | 65,205,000Source | 71,673,000Source | 79,305,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -190,886,000Source | — | — | — |
| Income (Loss) from Equity Method InvestmentsUSD | — | — | — | — | — | — | — | 0Source | 0Source | -1,688,000Source | — | — |
| Interest and Other IncomeUSD | — | — | 3,926,000Source | 6,705,000Source | 4,647,000Source | 6,187,000Source | 3,573,000Source | 5,516,000Source | 19,289,000Source | 20,153,000Source | 18,307,000Source | 4,566,000Source |
| Nonoperating Income (Expense)USD | — | — | 3,501,000Source | 5,481,000Source | 4,243,000Source | 5,876,000Source | 3,485,000Source | 5,458,000Source | 18,429,000Source | 16,052,000Source | 472,000Source | -4,878,000Source |
| Operating ExpensesUSD | — | — | 44,901,000Source | 71,774,000Source | 51,560,000Source | 56,819,000Source | 46,092,000Source | 65,191,000Source | 209,315,000Source | 273,221,000Source | 327,832,000Source | 335,692,000Source |
| Operating Lease, ExpenseUSD | — | — | — | — | — | — | 1,069,000Source | 1,130,000Source | 4,355,000Source | 5,264,000Source | 642,000Source | 2,433,000Source |
| Operating Lease, Lease IncomeUSD | — | — | 700,000Source | — | 700,000Source | 800,000Source | 800,000Source | 300,000Source | 2,600,000Source | — | — | — |
| Research and Development ExpenseUSD | — | — | 31,164,000Source | 44,713,000Source | 30,721,000Source | 40,156,000Source | 32,003,000Source | 50,200,000Source | 150,152,000Source | 192,299,000Source | 242,914,000Source | 256,387,000Source |
Offerings
Registration 333-298268
Filing attachments
d283634dex991.htm · 8-K · 2026-04-15
EX-99.1 4 d283634dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Allogene Therapeutics Announces Proposed Public Offering of $175 Million of Common Stock SOUTH SAN FRANCISCO, Calif., April 13, 2026 (GLOBE NEWSWIRE) - Allogene Therapeutics, Inc. (Nasdaq: ALLO) today announced that it intends to offer and sell, in an underwritten public offering and subject to market and other conditions, $175 million of shares of its common stock. All of the shares are being offered by Allogene. In addition, Allog…
Read attachment ↗d283634dex992.htm · 8-K · 2026-04-15
EX-99.2 5 d283634dex992.htm EX-99.2 EX-99.2 Exhibit 99.2 Allogene Therapeutics Announces Pricing of Public Offering of Common Stock SOUTH SAN FRANCISCO, Calif., April 14, 2026 - Allogene Therapeutics, Inc. (Nasdaq: ALLO) today announced the pricing of an underwritten public offering of 87,500,000 shares of its common stock at a price to the public of $2.00 per share. The gross proceeds from this offering are expected to be $175 million, before deducting underwriting discounts and commissi…
Read attachment ↗